Prevalence of and factors associated with extraintestinal manifestations and their remission in inflammatory bowel disease: the EXTRA prospective study from the GETAID.

Date publication

août 2023

Journal

Clinical and translational gastroenterology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Guillo L, Savoye G, Amiot A, Gilletta C, Nachury M, Dib N, Bourreille A, Roblin X, Caillo L, Allez M, Picon L, Hébuterne X, Seksik P, Chupin A, Buisson A, Brixi H, Altwegg R, Simon M, Amil M, Laharie D, Bouguen G, Serrero M, Elgharabawy Y, Peyrin-Biroulet L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37523417

Résumé

Extraintestinal manifestations (EIM) of inflammatory bowel disease (IBD) are challenging clinical situation. No prospective study assessed remission risk factors for EIMs. Study aimed to prospectively investigate the epidemiology, risk factors for EIM occurrence and EIM remission in a large IBD cohort.

Référence

Clin Transl Gastroenterol. 2023 08 1;: